General Information

PSA Decline is a Potential Biomarker for Identifying Early Resistance to Zytiga and Xtandi In Men Who are Post Chemotherapy*

Abiraterone Acetate (Zytiga) and enzalutamide (Xtandi) are the newest generation hormonal agents. They both have demonstrated a survival advantage in men with castrate resistant prostate cancer (CRPC) who have already been treated with docetaxel (chemotherapy). Unfortunately all men who are responsive to both of these drugs eventually become resistant. Some men are subject to early [...]

By Malecare|2017-10-19T10:48:08-04:00July 9th, 2014|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Drugs & Treatments, enzalutamide, General Information, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Defaulting Cancer Treatment Is Associated with Psychological Distress and A Desire for Psychological Support*

Sometimes some of us just simply decide that we will not start any treatment or continue a treatment protocol simply because we don’t want to have treatment. This type of decision is different from our deciding that a specific treatment has too many side effects for the potential upside it might provide. Researchers set out [...]

By Malecare|2014-07-08T09:56:48-04:00July 8th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, How We Live, mental health, Research, Uncategorized, Understanding APC|0 Comments

What you Need to Know About Denosumab (Xgeva)

Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]

By Malecare|2014-06-19T09:53:16-04:00June 19th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, denosumab - Xgeva, Drugs & Treatments, General Information, Uncategorized, Understanding APC, Xgeva|0 Comments

ASCO 2014 – Exercise Cuts Cytokines in Prostate Cancer

Research released at the ASCO meeting in Chicago confirms that regular exercise is a must for men with advanced prostate cancer. It was found that a regular and structured physical exercise program reduces cytokine production which is related to depression and to the inflammatory processes. According to the researchers these factors may impact prostate cancer [...]

By Malecare|2017-10-19T10:48:09-04:00June 6th, 2014|Advanced Prostate Cancer, ASCO, Drugs & Treatments, General Information, Quality of Life, Research, Uncategorized, Understanding APC|0 Comments

NICE Rejects Zytiga for Men Without Chemotherapy Exposure

The National Institute for Health and Care Excellence (NICE), which is Britain’s healthcare cost-effectiveness agency, has determined that abiraterone (Zytiga) was not worth giving to men with castrate resistant metastatic prostate cancer who have yet to had chemotherapy. Unlike the FDA in the United States which rules only on a drug’s efficacy, NICE decides if [...]

By Malecare|2014-05-14T10:53:53-04:00May 14th, 2014|Advanced Prostate Cancer, General Information, NICE, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|4 Comments

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer. Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

By Malecare|2023-07-08T15:52:28-04:00April 28th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, immunotherapy, ipilimumab, Prostvac, Provenge, teleconferences, vaccines|1 Comment

Understanding What Are Circulating Tumor Cells And What Is Their Role In Prostate Cancer Treatment

Circulating tumor cells (CTCs) is an area we will continue to hear more about as their importance to our understanding prostate cancer continues to increase. CTCs show the movement of cancer cells though the body. It is believed that these CTCs are the method that cancer uses to spread through our body (metastasize). Measuring the [...]

By Malecare|2017-10-19T10:48:26-04:00April 23rd, 2014|Advanced Prostate Cancer, biomarkers, Drugs & Treatments, General Information, Research, Uncategorized, Understanding APC|0 Comments

Data Links Bisphosphonates and Atrial Fibrillation (AF)

A large meta-analysis of nine studies showed that both oral and IV bisphosphonates were associated with a significantly increased risk of new-onset atrial-fibrillation (AF). The analysis also showed that the risk was greater with the IV drugs. According to the lead author, Dr Abhishek Sharma (Maimonides Medical Center, Brooklyn, NY.) the meta-analysis suggests that bisphosphonates [...]

By Malecare|2014-03-27T13:16:36-04:00March 27th, 2014|Advanced Prostate Cancer, bisphosphonates, Bone Mineral Density, Drugs & Treatments, General Information, Research|0 Comments

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By Malecare|2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Analyzing Time to Developing Castration-Resistant Prostate Cancer and Overall Survival after Initiating Androgen Deprivation Therapy (ADT)

There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can both delay the onset to castrate resistance as well as provide for a longer overall survival (OS). In a research [...]

By Malecare|2017-10-19T10:48:31-04:00March 11th, 2014|Advanced Prostate Cancer, CAB, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|4 Comments